Chester County News and Community Website
YARDLEY, PA — Optinose (NASDAQ: OPTN) has released its financial results for the third quarter of 2024, revealing an increase in net revenue from its flagship product, XHANCE, and adjustments …
Optinose Reports Q3 2024 Financial Results, Highlights XHANCE Performance Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) is set to disclose its financial results for the third quarter of 2024, along with key corporate updates, on Tuesday, November 12, 2024, before the …
Optinose to Announce Q3 2024 Financial Results with Investor Call Read More YARDLEY, PA — Optinose, Inc. (NASDAQ: OPTN) has announced the allocation of non-qualified stock option awards to eight newly hired employees as part of their recruitment strategy. This move is designed …
Optinose Grants Stock Options to Attract New Talent Read More YARDLEY, PA — Optinose (NASDAQ:OPTN) has appointed Terry Kohler as its new Chief Financial Officer, a strategic addition to the company’s executive team aimed at driving financial leadership and growth. Kohler …
Optinose Appoints Terry Kohler as Chief Financial Officer Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced the publication of a paper in the International Forum of Allergy & Rhinology, shedding light on the effectiveness of EDS-FLU (XHANCE) in treating …
New Study Highlights XHANCE’s Efficacy in Treating Chronic Rhinosinusitis Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) will deliver a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference.
Optinose to Present at Global Investment Conference Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) has released its financial results for the quarter ending June 30, 2024, along with key operational updates.
Optinose Reports Q2 2024 Financial Results and Operational Highlights Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) will release its financial results for the second quarter of 2024 before the market opens on Thursday, August 8, 2024.
Optinose to Announce Q2 2024 Financial Results and Host Conference Call Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) announced this week that its drug XHANCE® (fluticasone propionate) has been added to Express Scripts’ national formularies. These include the National Preferred, Flex, and …
Optinose’s XHANCE Added to Express Scripts’ National Formularies Read More YARDLEY, PA — Optinose (NASDAQ: OPTN) is slated to share a comprehensive company overview at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024, at 11:30 a.m. …
Optinose to Provide Business Update at H.C. Wainwright Conference Read More